Manages vasospastic angina confirmed. ANDA 75289, held by Valeant Pharms North. Nifedipine.
As of Nov 16, 2026, ANDA 75289 (Nifedipine), held by Valeant Pharms North, was first approved by FDA on Sep 27, 2000, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE I. Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 27, 2000 | Original application | Approved |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Rx |
| Sep 8, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Dec 16, 2002 | Supplement 5Manufacturing | Approved | None posted |
| Jul 15, 2002 | Supplement 2Manufacturing | Approved | None posted |
| Jun 4, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Dec 28, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Feb 6, 2001 | Supplement 1Manufacturing | Approved | |
| Sep 27, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters